Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial.

EClinicalMedicine · 2022 · PMC9481336 · PMID 36128334

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

almost significantp = 0·051so close (0.05 < p ≤ 0.1)

Patients with an eGFR (CKD-EPI ml/min/1.73m 2 ) rate below the median 71 at baseline showed almost significant benefit from the canakinumab treatment compared to placebo (WR 1·92 (1·00, 3·70), p = 0·051) vs patients with an eGFR above 71 (WR 0·74 (0·37, 1·48), p = 0·395).

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.